← Leaderboards
Michelle Alice Kelliher
Univ Of Massachusetts Med Sch Worcester
$16,226,746
Attributed
$17,203,766
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,203,766 · 8
By mechanism
R01$16,792,516 · 6
R56$406,250 · 1
R13$5,000 · 1
Top collaborators
- Narendra Wajapeyee4 shared
- John D Crispino1 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Kevin O'Connor$152,605
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingCellsPathway InteractionsApoptosisComplexBaseSignal TransductionMouse ModelGenesInflammatoryImmuneIn VivoMutationProteinsResponseMalignant NeoplasmsToll-Like ReceptorsCytokineMolecularInfectionInnovationTargeted TreatmentTnf GeneViral
Grant awards (52)
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$461,997
R01 · FY2025 · CA · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$397,813
R01 · FY2025 · CA · contact PI
Rip Proteins in Innate Immune Signaling$502,500
R01 · FY2024 · AI · contact PI
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$438,898
R01 · FY2024 · CA · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$377,922
R01 · FY2024 · CA · contact PI
Rip Proteins in Innate Immune Signaling$21,006
R01 · FY2024 · AI · contact PI
Rip Proteins in Innate Immune Signaling$502,500
R01 · FY2023 · AI · contact PI
Role of EZH2 as a Driver and Therapeutic Target of Hepatocellular Carcinoma$478,872
R01 · FY2023 · CA · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$397,813
R01 · FY2023 · CA · contact PI
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia$366,406
R01 · FY2023 · NS · contact PI
Rip Proteins in Innate Immune Signaling$131,069
R01 · FY2023 · AI · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$569,273
R01 · FY2022 · CA · contact PI
Rip Proteins in Innate Immune Signaling$502,500
R01 · FY2022 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$397,813
R01 · FY2022 · CA · contact PI
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia$366,406
R01 · FY2022 · NS · contact PI
Rip Proteins in Innate Immune Signaling$110,061
R01 · FY2022 · AI · contact PI
Rip Proteins in Innate Immune Signaling$502,500
R01 · FY2021 · AI · contact PI
Rip Proteins in Innate Immune Signaling$494,935
R01 · FY2020 · AI · contact PI
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis$358,031
R01 · FY2020 · CA · contact PI
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis$347,289
R01 · FY2019 · CA · contact PI
Rip Proteins in Innate Immune Signaling$418,750
R01 · FY2018 · AI · contact PI
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis$358,031
R01 · FY2018 · CA · contact PI
Rip Proteins in Innate Immune Signaling$418,750
R01 · FY2017 · AI · contact PI
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis$358,031
R01 · FY2017 · CA · contact PI
Rip Proteins in Innate Immune Signaling$418,750
R01 · FY2016 · AI · contact PI
Mechanism(s) of TAL1-and NOTCH1-mediated Leukemogenesis$358,031
R01 · FY2016 · CA · contact PI
Rip Proteins in Innate Immune Signaling$418,750
R01 · FY2015 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$319,752
R01 · FY2015 · CA · contact PI
Rip Proteins in Innate Immune Signaling$417,292
R01 · FY2014 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$310,160
R01 · FY2014 · CA · contact PI
Rip Proteins in Innate Immune Signaling$340,995
R01 · FY2013 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$300,567
R01 · FY2013 · CA · contact PI
Rip Proteins in Innate Immune Signaling$362,760
R01 · FY2012 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$319,752
R01 · FY2012 · CA · contact PI
Rip Proteins in Innate Immune Signaling$362,760
R01 · FY2011 · AI · contact PI
Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis$319,752
R01 · FY2011 · CA · contact PI
FASEB SRC on Hematopoietic Malignancies$5,000
R13 · FY2011 · CA
Rip Proteins in Innate Immune Signaling$365,774
R01 · FY2010 · AI · contact PI
Rip Proteins in Innate Immune Signaling$368,344
R01 · FY2009 · AI · contact PI
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis$315,864
R01 · FY2008 · CA · contact PI
Rip Proteins in Innate Immune Signaling$406,250
R56 · FY2007 · AI · contact PI
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis$315,864
R01 · FY2007 · CA · contact PI
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis$325,297
R01 · FY2006 · CA · contact PI
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis$332,186
R01 · FY2005 · CA
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$109,200
R01 · FY2005 · GM
Mechanism(s) of TAL-1/SCL-mediated Leukemogenesis$332,100
R01 · FY2004 · CA
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$218,400
R01 · FY2004 · GM
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$218,400
R01 · FY2003 · GM
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$14,000
R01 · FY2003 · GM
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$117,000
R01 · FY2002 · GM
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$117,000
R01 · FY2001 · GM
ANTI-APOPTOTIC SIGNALS MEDIATED BY RIP$114,600
R01 · FY2000 · GM